IP Library Granted Patent US 8,440,640
Granted Patent B2
US 8,440,640 · App. 13/129,586 · Granted May 14, 2013

Methods and compositions for treating obesity and related disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,640
App. No.
13/129,586
Granted
May 14, 2013
Kind
B2
Abstract

The invention provides methods for, and compositions effective for, treating obesity, inhibiting weight gain, treating diabetes mellitus, inhibiting atherosclerosis and treating related disorders and conditions comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient. The compound capable of inhibiting AC5 may be administered singly or in combination with another agent. In some embodiments, the AC5 inhibiting compound is 9-β-D-arabinofuranosyladenine (AraAde). The compounds may be administered in an amount of about 1 to about 200 mg/kg/day, about 1 to about 100 mg/kg/day, about 10 to about 80 mg/kg/day, about 12 to about 40 mg/kg/day or about 15 to about 25 mg/kg/day. In some embodiments, the compound is administered orally.

Claims (12)

1. A method of treating obesity comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient.

2. A method according to claim 1 wherein the AC5 inhibiting compound is 9-β-9-β-arabinofuranosyladenine (AraAde).

3. A method according to claim 1 wherein the AC5 inhibiting compound is administered in an amount of about 1 to about 100 mg/kg/day.

4. A method according to claim 1 wherein the AC5 inhibiting compound is administered in an amount of about 10 to about 40 mg/kg/day.

5. A method according to claim 1 wherein the AC5 inhibiting compound is administered in an amount of about 15 to about 25 mg/kg/day.

6. The method of claim 1 wherein the compound is administered parenterally.

7. A method of treating diabetes mellitus comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient.

8. A method according to claim 7 wherein the AC5 inhibiting compound is 9-β-9-β-arabinofuranosyladenine (AraAde).

9. A method according to claim 7 wherein the AC5 inhibiting compound is administered in an amount of about 1 to about 100 mg/kg/day.

10. A method according to claim 7 wherein the AC5 inhibiting compound is administered in an amount of about 10 to about 40 mg/kg/day.

11. A method according to claim 7 wherein the AC5 inhibiting compound is administered in an amount of about 15 to about 25 mg/kg/day.

12. The method of claim 7 wherein the compound is administered parenterally.

Assignments (2)
NUNC PRO TUNC ASSIGNMENT Recorded Sep 6, 2013
From: THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 031152/0452 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2012
From: VATNER, STEPHEN F.
To: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Reel/Frame 028829/0266 →